Volume 12, Number 1—January 2006
Dispatch
Neutralizing Antibodies in Survivors of Sin Nombre and Andes Hantavirus Infection
Table
Patient | Origin | Years after infection | AND NAb titer | SNV NAb titer |
---|---|---|---|---|
1 | Chile | 3 | >1:1,600 | 1:100 |
2 | Chile | 4 | 1:400 | <1:100 |
3 | Chile | 7 | >1:1,600 | <1:100 |
4 | Chile | 0.7 | 1:400 | <1:100 |
5 | Chile | 4 | 1:400 | <1:100 |
6 | Chile | 1 | 1:400 | <1:100 |
7 | Chile | 4 | 1:800 | 1:100 |
8 | Chile | 3 | 1:200 | <1:100 |
9 | Chile | 4 | >1:1,600 | <1:100 |
10 | Chile | 7 | 1:400 | <1:100 |
11 | Chile | 1 | 1:400 | <1:100 |
12 | USA | 1 | <1:100 | 1:800 |
13 | USA | 3 | <1:100 | 1:400 |
14 | USA | 4 | <1:100 | 1:400 |
15 | USA | 4 | 1:100 | >1:1,600 |
16 | USA | 3 | <1:100 | 1:400 |
17 | USA | 5 | <1:100 | >1:1,600 |
18 | USA | 11 | <1:100 | 1:400 |
19 | USA | 6 | <1:100 | 1:800 |
20 | USA | 4 | <1:100 | >1:1,600 |
Page created: February 21, 2012
Page updated: February 21, 2012
Page reviewed: February 21, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.